April 3 (Reuters) - The U.S. Food and Drug Administration has approved the expanded use of Amgen's AMGN.O drug, Uplizna, to help reduce the risk of flares in patients with a rare immune system-related condition, the regulator said on Thursday.
(Reporting by Siddhi Mahatole, Mariam Sunny and Puyaan Singh in Bengaluru and Deena Beasley in Los Angeles; Editing by Alan Barona)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.